Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$227.76 USD
-1.08 (-0.47%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $227.64 -0.12 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BDX 227.76 -1.08(-0.47%)
Will BDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDX
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?
BDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
Earnings Season Update and Analyst Reports for Broadcom, JNJ & Verizon
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
Other News for BDX
BD to Announce Financial Results for its Third Quarter of Fiscal 2024
GSH Unveils New Upscale Hotel in Chongqing
ICU Medical - Stabilization Is In Sight, But The Road Back Is Difficult
New BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases
Dividend Champion, Contender, And Challenger Highlights: Week Of June 23